Resected stage II or stage III adenocarcinoma of the colon
Conditions
Interventions
Trade Name: Avastin
Product Name: Bevacizumab
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: Bevacizumab
Current Sponsor code: rhuMAb VEGF,RO4876646
Concentration unit
Sponsors
All Ireland Cooperative Oncology Research Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Male and female patients. IRB approved written informed consent form must be signed. Patients must be >_18years old. Randomisation must occur during the 3 week interval beginning on post-operative Day 29 and ending postoperative day 50. Distal extent of tumour must be >_12 cm from the anal verge on endoscopy, then the distal extent of tumour must be >_12cm from the anal verge as determined by surgical resection, are eligible. Patient must have had an en bloc complete gross resection of tumour (curative resection) by open laparatomy or laparoscopically-assisted colectomy. Patients who have had a two-stage surgical procedure, to first provide decompressive colostomy and then in a later procedure to have the definitive surgical resection, are eligible. Patients must have histologically confirmed adenocarcinoma of the colon that meets one of the criteria below: 1. Stage II carcinoma (T3,4,N0, M0). The tumour invades through the muscularis propria into the subserosa or into non-peritonealized pericolic or perirectal tissues (T3); or directly invades other organs or structures, and/or perforates visceral peritoneum (T4). 2. Stage III carcinoma (any T N1,2 M0).The tumour has invaded to any depth with involvement of regional lymph nodes. Patients with T4 tumours that have involved an adjacent structure (e.g bladder, small intestine,ovary,etc) by direct extension from the primary tumour are eligible if all of the following conditions are met: - all or a portion of the adjacent tumour was removed en bloc with the primary tumour; - in the opinion of the surgeon, all grossly visible tumour was completely resected (''curative resection'') - histologic evaluation by the pathologist confirms the margins of the resected specimen are not involved by malignant cells, and - local radiation therapy will not be utilized - patients with more than one synchronous primary colon tumour are eligible - in the opinion of the investigator,patients must have a life expectancy of at least 5 years, excluding their diagnosis of cancer. - patients must have an ECOG performance status of 0 or 1 - at the time of randomisation, the postoperative absolute granulocyte count (AGC) must be >_1500/mm3 (or _ 100,000/mm3 - there must be postoperative evidence of adequate hepatic function *bilirubin must be _1.0 must undergo a 24 hour urine collection, which must be an adequate collection and must demonstrate _5 years and are deemed by their physician to be at low risk for rcurrence.Patients with squamous or basal cell carcinoma of the skin, melanoma in situ, carcinoma in situ of the cervix, or carcinoma in situ of the colon or rectum that have been effectively treated are elig
Exclusion criteria
Exclusion criteria: - colon tumour other than adenocarcinoma, i.e sarcoma, lymphoma, carcinoid,etc - rectal tumours, i.e a tumour located 150/90mmHg - previous history of any CNS cerebrovascular ischemia -History of peripheral arterial ischemia within 6 months -history of visceral arterial ischemia within 6 months -PT (INR) >1.5, unless the patient is on full-dose anti-coagulants. If so, the following criteria must be met for enrollment *subject must have an in range INR (2-3) on a stable dose of warfarin or on a stable dose of low molecular weight heparin *subject must not have active bleeding or a pathological condition that is associated with a high risk of bleeding - concomitant halogenated antiviral agents -clinically significant peripheral neuropathy at the time of randomisation (NCI CTC version 3.0) as grade 2 or greater neurosensory or neuromotor toxicity -non malignat systemic disease that would preclude any of the study therapy drugs *New York heart association class II or IV myocardial disease *myocardial infarction within 6 months of study entry *unstable angina within 6 months of study entry *current symptomatic arrhythmia -pregnant or lactatation at the time of proposed randomisation.Eligible patients of reproductive potential (both sexes) must agree to use adequate contraceptive methods during study therapy and for at least 3 months after the completion of bevacizumab. -Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objective of the trial is to compare the relative efficacy of mFOLFOX6 + bevacizumab with that of mFOLFOX6 alone in prolonging disease free survival (DFS).;Secondary Objective: The secondary objective of the trial is to compare the relative efficacy of mFOLFOX6 + bevacizumab with that of mFOLFOX6 alone in prolonging survival (S).;Primary end point(s): The primary endpoint to be used for statistical analysis is duration of DFS. Events for DFS include first documented evidence of colon cancer recurrence, second primary cancer, or death from any cause. | — |
Countries
Ireland
Outcome results
None listed